InflaRx Bilan de santé

Santé financière contrôle des critères 4/6

InflaRx possède un total de capitaux propres de €65.3M et une dette totale de €0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont €79.7M et de €14.4M.

Informations clés

Ratio d'endettement

€0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	€26.21m
Fonds propres	€65.28m
Total du passif	€14.41m
Total des actifs	€79.69m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de IF0 ( €73.6M ) dépassent ses passifs à court terme ( €13.9M ).

Passif à long terme: Les actifs à court terme de IF0 ( €73.6M ) dépassent ses passifs à long terme ( €535.8K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: IF0 est sans dette.

Réduire la dette: IF0 n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: IF0 dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: IF0 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 5 % chaque année

InflaRx Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Revenue and earnings growth

InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

New major risk - Financial position

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

Forecast breakeven date moved forward to 2024

New major risk - Share price stability

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast to breakeven in 2025

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

Inflarx Announces Positive Topline Results for Vilobelimab from the U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study

New 90-day high: €5.29

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

Inflarx Provides an Update on the Ongoing Development of Vilobelimab (Ifx-1), First-In-Class Anti-C5a Antibody

New 90-day high: €4.60

InflaRx N.V. Completes Enrollment in Vilobelimab (Ifx-1) European Phase Ii Study in Anca-Associated Vasculitis

InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer

New 90-day low - €3.04

New 90-day low - €3.46

New 90-day low - €3.98

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines